Who Paid My Doc
Jeffrey Jaeger
Addiction Medicine Camden, NJ Medical Doctor
NPI 1265469175 CMS profile 627533
800 Cooper St Ste 4004Th, 7Th Fl Ste 760, Camden, NJ 08102
General payments
$0
Research payments
$150
Ownership & investment interest
$0
Through program year 2020, Jeffrey Jaeger of Camden, NJ is reported in the CMS Open Payments database as having received $0 across 0 general payments and $150 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 40th percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
1 row| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2020 | Research | $150 | 1 |
Prescribing to Medicare patients
Part D · data year 2024 · 77 drugsPart D claims
2,305
Drug cost
$212,347
Branded share of claims
23%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Trulicity Dulaglutide | Brand | 43 | $46,588 | |
| Eliquis Apixaban | Brand | 30 | $35,854 | |
| Ozempic Semaglutide | Brand | 30 | $27,044 | |
| Jardiance Empagliflozin | Brand | 17 | $22,491 | |
| Mounjaro Tirzepatide | Brand | 13 | $20,938 | |
| Spiriva Respimat Tiotropium Bromide | Brand | 12 | $7,236 | |
| Amlodipine-Valsartan-Hctz Amlodipine/Valsartan/Hcthiazid | Brand | 14 | $6,993 | |
| Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl | Brand | 45 | $5,280 | |
| Diovan Hct Valsartan/Hydrochlorothiazide | Brand | 11 | $5,242 | |
| Atorvastatin Calcium | Generic | 216 | $3,213 |
The 10 drugs with the highest cost, of 77 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 19 billing codesPaid by Medicare
$13,477
Medicare patients
160
Services billed
342
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 68% | |
| Arthritis | 33% | |
| Diabetes | 22% | |
| Ischemic heart disease | 22% | |
| Atrial fibrillation | 19% | |
| Chronic kidney disease | 18% | |
| Cancer | 18% | |
| Depression | 16% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Addiction Medicine in New Jersey
Related records
Addiction Medicine in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Addiction Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.